Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 12

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 12
---
 Profit for the Period attributable to owners of the Company was JPY 211.1 billion ( JPY +64.0 billion and +43.5% AER, +32.0% CER).

<div align='center'>6</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

(ii) Results of Core Financial Measures (April 1 to December 31, 2024)

Definition and Explanation of Core Financial Measures and Constant Exchange Rate Change

In addition to the financial statements in accordance with IFRS, Takeda uses the concept of Core Financial Measures for measuring financial performance. These measures are not defined by International Financial Reporting Standards (IFRS). See “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix for additional information.

#### Results of Core Operations
|                                                                      |     |           |         |     |                  |         |     |          |       |     |          |      |   |     |     |      | Billion JPY or percentage |
|                                                                      |     | FY2023 Q3 |         |     | FY2024 Q3        |         |     | AER      |       |     |          |      |   |     | CER |      |                           |
|                                                                      |     |           |         |     | Amount of Change |         |     | % change |       |     | % change |      |   |     |     |      |                           |
| Core revenue                                                         |     |           | 3,212.9 |     |                  | 3,528.2 |     |          | 315.3 |     |          |  9.8 | % |     |     |  4.5 | %                         |
| Core operating profit                                                |     |           |   865.6 |     |                  | 1,006.3 |     |          | 140.7 |     |          | 16.3 | % |     |     | 10.1 | %                         |
| Core net profit for the period                                       |     |           |   643.7 |     |                  |   699.1 |     |          |  55.4 |     |          |  8.6 | % |     |     |  1.9